Estrogen-progestin replacement therapy and endometrial cancer

Journal of the National Cancer Institute

Volumn 89, Issue 15, 1997, Pages 1110-1116

  Pike, Malcolm C ^a   Peters, Ruth K ^a   Cozen, Wendy ^a   Probst Hensch, Nicole M ^a   Felix, Juan C ^b   Wan, Peggy C ^a   Mack, Thomas M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE;

EID: 0030854472     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.15.1110     Document Type: Article

References (23)

1. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293: 1164-7.
2. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
3. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262-7.
4. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
5. Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore (MD): Williams & Wilkins, 1994.
6. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-51.
7. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
8. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993;81:265-71.
9. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20-4.
10. Jick SS. Combined estrogen and progesterone use and endometrial cancer [letter]. Epidemiology 1993;4:384.
11. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
12. Henderson BE, Gordon RJ, Menck H, Soohoo J, Martin SP, Pike MC. Lung cancer and air pollution in southcentral Los Angeles County. Am J Epidemiol 1975;101:477-88.
13. Changes in gynecologic staging by the International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1990;162:610-1.
14. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ, 1980;32:5-338.
15. King RJ, Whitehead MI. Progestin action in relation to the prevention of endometrial abnormalities. In: Raynaud JP, Ojasoo T, Martini L, editors. Medical management of endometriosis. New York: Raven Press, 1984: 67-77.
16. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI. Is Provera the ideal progestogen tor addition to postmenopausal estrogen therapy? Fertil Steril 1986;45:345-52.
17. Flowers CE Jr, Wilborn WH, Hyde BM. Mechanisms of uterine bleeding in postmenopausal patients receiving estrogen alone or with a progestin. Obstet Gynecol 1983;61:135-43.
18. Paterson ME, Wade-Evans T, Sturdee DW, Thorn MH, Studd JW. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 1980;22:822-4.
19. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-605.
20. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
21. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21.
22. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis 1987;40 Suppl 2:59S-69S.
23. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693-700.